OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.
Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential.
IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 2023.
Multibillion-dollar DED market whose medical needs remain largely unmet.
AmbioPharm supporting OK-101 program with peptide synthesis and development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.